Comparing the current results to its competitors, Insmed Inc reported Revenue increase in the 2 quarter 2026 by 393.78 % year on year. The sales growth was above Insmed Inc's competitors' average revenue growth of 7.3 %, achieved in the same quarter.
Insmed Inc's Comment on Competition and Industry Peers
The biotechnology and pharmaceutical industries are competitive, with potential competitors including commercial pharmaceutical, biotechnology, and device companies, academic institutions, scientists, smaller or early-stage companies, and non-profit organizations developing drugs for anti-infective, respiratory, inflammatory, immunology, oncology, and rare diseases. Competitors may have greater resources and more advanced product candidates that could reach the market before the company's products. They may also develop products that are more effective, safer, less expensive, or offer better tolerability or convenience. The company may face generic competitors supported by third-party payors. The company holds a Commercialization Agreement with PARI, which restricts certain third parties considered competitors to PARI. Additionally, the company has a contract manufacturing agreement with Therapure Biopharma Inc., now assumed by Resilience, for manufacturing ARIKAYCE. In the lung disease market, major competitors include pharmaceutical and biotechnology companies, with existing approved products for some indications such as pulmonary arterial hypertension (PAH), including other formulations of treprostinil.
Optinose Inc is a pharmaceutical company that specializes in developing and commercializing innovative therapies delivered through its proprietary device called Optinose Exhalation Delivery System. They generate revenue by licensing and selling their treatment products for conditions like nasal polyps and migraines.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.
Sources:
Insmed Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Insmed Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
